Results 251 to 260 of about 5,838,181 (363)

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem   +9 more
wiley   +1 more source

Mechanistic insights into the antiproliferative effect of the redox-active iron chelator Dp44mT on multiple myeloma cell lines. [PDF]

open access: yesHematol Transfus Cell Ther
Sharma A   +6 more
europepmc   +1 more source

"Myeloma protein" in a patient with monocytic leukemia.

open access: yesBlood, 1969
M. D. Poulik, L. Berman, A. Prasad
semanticscholar   +1 more source

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG‐MM5 Trial

open access: yesEuropean Journal of Haematology, Volume 116, Issue 3, Page 226-234, March 2026.
ABSTRACT Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to ...
Tim Richardson   +125 more
wiley   +1 more source

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM) [PDF]

open access: hybrid
Huishou Fan   +20 more
openalex   +1 more source

Plasma Proteomic Profile of Chemotherapy‐Induced Severe Neutropenia: A Pilot Discovery Phase Study

open access: yesThe FASEB Journal, Volume 40, Issue 3, 15 February 2026.
Immune system, hemostasis, and protein metabolism are the major biological mechanistic effects affected by chemotherapy‐induced myelotoxicity treatment, which may underline tissue damage and systemic responses seen in patients' follow‐up treatment. ABSTRACT Transient severe neutropenia and thrombocytopenia are frequent during treatment of hematological
Leticia Queiroz da Silva   +10 more
wiley   +1 more source

Bortezomib-Induced Sensorineural Hearing Loss May Be Reversible with Intratympanic Dexamethasone. [PDF]

open access: yesHematol Rep
Peláez Casillas N   +4 more
europepmc   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang   +7 more
wiley   +1 more source

A Case of Atypical Acute Encephalopathy Unmasking IgA Multiple Myeloma. [PDF]

open access: yesCureus
Abad JT   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy